Next Science Ltd traded at 0.63 this Friday February 3rd, increasing 0.04 or 6.84 percent since the previous trading session. Looking back, over the last four weeks, Next Science Ltd gained 3.85 percent. Over the last 12 months, its price fell by 44.20 percent. Looking ahead, we forecast Next Science Ltd to be priced at 0.65 by the end of this quarter and at 0.60 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Ansell 28.62 0.60 2.14% 10.16%
Fisher & Paykel Healthcare 24.34 0.59 2.48% -11.72%
Mayne Pharma 3.02 -0.11 -3.51% -37.54%
Nanosonics Ltd 4.87 -0.09 -1.81% -3.56%
Polynovo Ltd 2.56 -0.03 -1.16% 99.22%
ResMed 32.31 0.31 0.97% -4.12%

Next Science Ltd
Next Science Limited is an Australia-based medical technology company. The Company's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. The Blast X is an antimicrobial wound gel.